Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07003841

Evaluation of Clinical Efficacy of Augmented Reality (AR)-Based Breast Cancer Medical Imaging Solution (SKIA-Breast) Localization Method in Breast Cancer Patients

This clinical trial aims to evaluate whether an augmented reality (AR)-based medical imaging solution (SKIA-Breast) is non-inferior to conventional ultrasound-guided skin marking in guiding breast-conserving surgery in female patients with breast cancer. Participants will be randomly assigned in a 1:1 ratio to either the AR-based group or the conventional group. All participants will undergo breast-conserving surgery according to their assigned method. The primary outcome is the negative margin resection rate evaluated by histopathological examination. The secondary outcome is the re-excision rate due to positive margins assessed by histopathological examination.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Breast Neoplasms Breast Diseases Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

19 year–80 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Ewha Womans University Medical Center, Seoul, Gangseo-gu, South Korea

Loading trial locations.

About this study

  • Background With the increasing incidence of early breast cancer due to advancements in diagnostic imaging and screening, breast-conserving surgery (BCS) has become more common, offering improved patient satisfaction and quality of life. Accurate lesion localization is critical for successful BCS. While several localization techniques exist, no single method is widely standardized. Augmented reality (AR) presents a promising non-invasive alternative, enabling real-time visual projection of lesion and lymph node positions onto the skin, potentially improving surgical accuracy and addressing limitations of conventional methods.
  • Purpose This study aims to evaluate the clinical efficacy of an AR-based medical imaging localization method (SKIA-Breast) compared to conventional ultrasound-guided skin marking in patients diagnosed with breast cancer who require breast-conserving surgery.
  • Procedure This multicenter, randomized, controlled clinical trial will assess whether the AR-based medical imaging solution (SKIA-Breast) is non-inferior to conventional ultrasound-guided skin marking in guiding breast-conserving surgery. Female patients with breast cancer will be randomly assigned in a 1:1 ratio to either the AR-based group or the conventional group. All participants will undergo breast-conserving surgery according to their assigned method.

The primary outcome is the negative margin resection rate, evaluated by histopathological examination.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects will be enrolled only when all the inclusion criteria are fully met.
  • Subjects who aged 19 to 80 years diagnosed with breast cancer through biopsy.
  • Subjects diagnosed with breast cancer who had both MRI and CT and ultrasound scans.
  • Patients diagnosed with breast cancer who are scheduled to undergo breast-conserving surgery, have not received neoadjuvant chemotherapy, and show no evidence of metastasis to other organs.
  • Tumor size criteria on ultrasound: : 5 mm ≤ tumor size ≤ 30 mm
  • Subjects whose biopsy pathology results are Invasive carcinoma.
  • Subjects who have a single lesion.
  • Subjects who have received a full explanation of the clinical trial fully understand its details, voluntarily decide to participate, and provide written informed consent.

Exclusion criteria

  • Subjects will be excluded from enrollment if they meet any of the exclusion criteria.
  • Subjects prohibited from both MRI, CT and Ultrasound scans.
  • Subjects with no lesions visible on CT.
  • Pregnant or lactating(i.e., breastfeeding) subjects.
  • Subjects who are biologically male.
  • Subjects with breast cancer who received neoadjuvant chemotherapy or who have metastasized to other organs
  • Subjects whose biopsy pathology results are Invasive lobular carcinoma
  • Subjects deemed unsuitable for the study according to judgment of the investigator

Treatment and study plan

Surgical navigation system with stereotactic guidance

Device

This investigational medical software device utilizes CT imaging data to project the scanned anatomy onto the patient's body, enabling augmented reality-based visualization of the lesion site before surgery

Other names: SKIA-Breast

General ultrasound imaging system

Device

A general diagnostic ultrasound imaging device that transmits ultrasound energy to the lesion for diagnostic purposes and visualizes the reflected signals. It supports various types of transducers and associated application software packages used for acquiring, displaying, and analyzing ultrasound data.

Primary outcomes

  1. Negative margin resection rate

    Time frame: within 4week after biopsy

    Each subject will have one surgical margin evaluated, with an independent pathologist determining margin status (negative or positive) based on the permanent postoperative pathology specimen. Measurements of the margin are taken in the medial, lateral, superior, and inferior directions in millimeters, with conservative rounding applied to decimal values.

Secondary outcomes

  1. re-excision rate

    Time frame: within 4week after biopsy

    Re-excision rate due to positive margins assessed by histopathological examination

  2. margin assessment

    Time frame: within 4week after biopsy

    In breast resections performed after the application of the investigational medical device, pathological assessment of the resection margins will be conducted by an independent evaluator (pathologist). Only the lateral, medial, superior, and inferior directions will be recorded, while the deep and superficial margins will be excluded.

    For analysis, the minimum value among the four recorded margins will be selected and classified into the following six categories:

    • Less than 2 mm
    • 2 mm to less than 5 mm
    • 5 mm to less than 10 mm
    • 10 mm to less than 20 mm
    • 20 mm to less than 30 mm
    • 30 mm or greater

  3. Tumor-to-gross area ratio of excised tissue

    Time frame: within 4week after biopsy

    Tumor-to-gross area ratio of excised tissue (excluding thickness) assessed by histopathology.

    Calculation formula: (Tumor surface area / Gross (tumor + margin) surface area) × 100 (%)

  4. User satisfaction

    Time frame: on the day of biopsy

    User satisfaction is assessed in the investigator's survey covering usability, safety, overall satisfaction, and reusability. This satisfaction is measured using a 5-point Likert scale, where higher scores indicate greater satisfaction following the application of the investigational medical device.

Study contacts

Contact information is provided by the study sponsor or research team.

Jeongmi LEE

CONTACT

[email protected]

+821048856620

Sponsors and collaborators

Lead sponsor

SKIA Inc.

Industry

Registry information

Official study title

Multicenter, Randomized, Controlled, Prospective, Confirmatory Study to Evaluate the Clinical Efficacy of Augmented Reality (AR)-Based Breast Cancer Medical Imaging Solution (SKIA-Breast) Localization Method in Breast Cancer Patients Confidential Statement

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Jun 4, 2025
Registry last updated
Mar 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.